Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Seelos Therapeutics Inc (SEEL)  
$0.11 0.00 (0.00%) as of 4:30 Mon 11/27


Download
   
Exchange: Nasdaq Small Cap
Security Type: Common
Shares Out: 102,230,000
Market Cap: 10.87(M)
Last Volume: 10,264,973 Avg Vol: 10,237,079
52 Week Range: $0.1063 - $1.64
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    NASDAQ COMPOSITE     NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Seelos Therapeutics is a clinical-stage biopharmaceutical company focused on the development of products that address unmet needs in Central Nervous System disorders and other disorders. Co.'s primary programs are SLS-002 for the potential treatment of Acute Suicidal Ideation and Behavior in patients with Major Depressive Disorder and SLS-005 for the potential treatment of Amyotrophic Lateral Sclerosis and Spinocerebellar Ataxia. Co. is also developing several preclinical programs, including SLS-004, SLS-006, and SLS-007 for the potential treatment of Parkinson's Disease, SLS-010 in narcolepsy and related disorders, and SLS-012, an injectable therapy for post-operative pain management.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 158,757 158,757
Total Buy Value $0 $0 $200,222 $200,222
Total People Bought 0 0 2 2
Total Buy Transactions 0 0 2 2
Total Shares Sold 0 0 0 0
Total Sell Value $0 $0 $0 $0
Total People Sold 0 0 0 0
Total Sell Transactions 0 0 0 0
End Date 2024-03-10 2023-12-08 2023-06-09 2022-06-09

   
Records found: 395
  Page 6 of 16  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Esber Henry Jemil Director   –       •      –    2010-12-14 4 A $0.00 $0 D/D 83,327 538,867     -
   Cox Edward M. VP of Corporate Development   •       –      –    2010-12-14 4 A $0.00 $0 D/D 18,749 133,105     -
   Crea Roberto Director   –       •      –    2010-12-14 4 A $0.00 $0 D/D 6,262 33,813     -
   Damaj Bassam President and CEO   •       •      –    2010-10-07 5 GD $0.00 $0 D/D 47,000 828,876     -
   Crea Roberto Director   –       •      –    2010-09-30 4 A $4.59 $9,001 D/D 1,961 25,590     -
   Ray Rusty Director   –       •      –    2010-09-30 4 A $4.59 $10,002 D/D 2,179 6,537     -
   Oppenheim Leonard A Director   –       •      –    2010-09-30 4 A $4.59 $10,002 D/D 2,179 20,680     -
   Gillespie Deirdre Director   –       •      –    2010-09-30 4 A $4.59 $9,001 D/D 1,961 2,615     -
   Cox Edward M. VP of Corp. Development   •       •      –    2010-08-31 5 GD $0.00 $0 D/D 36,000 114,356     -
   Cox Edward M. VP of Corp. Development   •       –      –    2010-07-14 4 A $0.00 $0 D/D 60,935 150,356     -
   Oppenheim Leonard A Director   –       •      –    2010-06-30 4 A $4.59 $10,002 D/D 2,179 18,501     -
   Ray Rusty Director   –       •      –    2010-06-30 4 A $4.59 $10,002 D/D 2,179 4,358     -
   Gillespie Deirdre Director   –       •      –    2010-06-30 4 A $4.59 $3,002 D/D 654 654     -
   Berman Richard J Director   –       •      –    2010-06-30 4 A $4.59 $6,004 D/D 1,308 23,965     -
   Crea Roberto Director   –       •      –    2010-06-30 4 A $4.59 $9,001 D/D 1,961 23,629     -
   Cox Edward M. VP of Corp. Development   •       –      –    2010-06-21 4 A $2.52 $132,537 D/D 52,594 89,421     -
   Crea Roberto Director   –       •      –    2010-06-21 4 A $2.52 $33,574 D/D 13,323 21,668     -
   Damaj Bassam President and CEO   •       •      –    2010-06-21 4 A $2.52 $513,536 I/I 203,784 327,100     -
   Damaj Bassam President and CEO   •       •      –    2010-06-21 4 A $2.52 $1,218,097 D/D 483,372 875,876     -
   Esber Henry Jemil EVP Pre-Clinical Business Dev.   •       •      –    2010-06-21 4 A $2.52 $302,080 I/I 119,873 192,412     -
   Esber Henry Jemil EVP Pre-Clinical Business Dev.   •       •      –    2010-06-21 4 A $2.52 $589,055 D/D 233,752 381,870     -
   Liu Vivian H Executive Vice President   •       •      –    2010-05-24 4 A $0.00 $0 D/D 1,302,631 2,743,631     -
   Damaj Bassam President and CEO   •       •      –    2010-05-24 4 A $0.00 $0 D/D 1,500,000 5,887,559     -
   Cox Edward M. VP of Corp. Development   •       –      –    2010-04-09 4 A $0.00 $0 D/D 75,000 552,396     -
   Westgate Mark Vice President & CFO   •       –      –    2010-04-09 4 A $0.00 $0 D/D 150,000 879,318     -
  395 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 6 of 16
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us